MedPath

Azurity Pharmaceuticals, Inc.

Azurity Pharmaceuticals, Inc. logo
🇺🇸United States
Ownership
Holding
Established
1998-01-01
Employees
11
Market Cap
-
Website
http://www.azurity.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

25

FDA:25

Drug Approvals

VIVIMUSTA

Approval Date
Mar 28, 2025
FDA

SOTYLIZE

Approval Date
Jan 24, 2024
FDA

Edarbi

Approval Date
Jan 23, 2024
FDA

ERYTHROMYCIN ETHYLSUCCINATE

Approval Date
Dec 16, 2023
FDA

E.E.S

Approval Date
Dec 16, 2023
FDA

Ery-Ped

Approval Date
Dec 16, 2023
FDA

FIRVANQ

Approval Date
Dec 8, 2023
FDA

FIRVANQ

Approval Date
Dec 8, 2023
FDA

Adthyza Thyroid

Approval Date
Dec 8, 2023
FDA

Zenzedi

Approval Date
Nov 10, 2023
FDA
  • Prev
  • 1
  • 2
  • 3
  • Next

Clinical Trials

No trials found

News

FDA Approves Nilotinib Tablets (Danziten) Without Mealtime Restrictions for CML

The FDA has approved nilotinib tablets (Danziten) for Philadelphia chromosome-positive chronic myeloid leukemia (CML) patients, offering a new treatment option.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.